[Skip to Content]
[Skip to Content Landing]
Citations 0
February 11, 2009

Incomplete Financial Disclosure in a Commentary on Testing for Fragile X Gene Mutations Throughout the Life Span

JAMA. 2009;301(6):601-602. doi:10.1001/jama.2009.79

To the Editor: I would like to sincerely apologize to the editors and readers of JAMA for failing to note in the financial disclosure of my Commentary1 that I am listed as a coinventor in a US Government Provisional Patent Application (Published Patent Application No. 20080113355) filed in 2006, one portion of which relates to a screening method for detecting expanded CGG repeats. The original funding/support statement is correct as given, as is the financial disclosure statement by my coauthor (R. J. Hagerman). However, I neglected to report the filed application, an omission that I now realize was an error in judgment on my part. I sincerely regret any lack of transparency that my failure to report this information may have created.

First Page Preview View Large
First page PDF preview
First page PDF preview